Pediatr Gastroenterol Hepatol Nutr.  2016 Jun;19(2):83-95. 10.5223/pghn.2016.19.2.83.

Hepatitis C Viral Infection in Children: Updated Review

• El-Guindi

• KMID: 2328168
• DOI: http://doi.org/10.5223/pghn.2016.19.2.83

Abstract

Hepatitis C virus (HCV) infection is a major medical challenge affecting around 200 million people worldwide. The main site of HCV replication is the hepatocytes of the liver. HCV is a positive enveloped RNA virus from the flaviviridae family. Six major HCV genotypes are implicated in the human infection. In developed countries the children are infected mainly through vertical transmission during deliveries, while in developing countries it is still due to horizontal transmission from adults. Minimal nonspecific and brief symptoms are initially found in approximately 15% of children. Acute and chronic HCV infection is diagnosed through the recognition of HCV RNA. The main objective for treatment of chronic HCV is to convert detected HCV viremia to below the detection limit. Children with chronic HCV infection are usually asymptomatic and rarely develop severe liver damage. Therefore, the benefits from current therapies, pegylated-Interferon plus ribavirin, must be weighed against their adverse effects. This combined treatment offers a 50-90% chance of clearing HCV infection according to several studies and on different HCV genotype. Recent direct acting antiviral (DAA) drugs which are well established for adults have not yet been approved for children and young adults below 18 years. The most important field for the prevention of HCV infection in children would be the prevention of perinatal and parenteral transmission. There are areas of focus for new lines of research in pediatric HCV-related disease that can be addressed in the near future.

Keyword

Hepatitis C virus; Hepatitis C viral infection; Children; Epidemiology; Diagnosis treatment; Direct acting antivirals

MeSH Terms

Adult
Child*
Developed Countries
Developing Countries
Epidemiology
Flaviviridae
Genotype
Hepacivirus
Hepatitis C*
Hepatitis*
Hepatocytes
Humans
Limit of Detection
Liver
Ribavirin
RNA
RNA Viruses
Viremia
Young Adult
RNA
Ribavirin

Reference

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244:359–362.

2. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015; 61:77–87.

3. Jhaveri R. Diagnosis and management of hepatitis C virus-infected children. Pediatr Infect Dis J. 2011; 30:983–985.

4. El-Raziky MS, El-Hawary M, Esmat G, Abouzied AM, El-Koofy N, Mohsen N, et al. Prevalence and risk factors of asymptomatic hepatitis C virus infection in Egyptian children. World J Gastroenterol. 2007; 13:1828–1832.

5. Baré P. Hepatitis C virus and peripheral blood mononuclear cell reservoirs Patricia Baré. World J Hepatol. 2009; 1:67–71.

6. Kato N. Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation. Microb Comp Genomics. 2000; 5:129–151.

7. Kim CW, Chang KM. Hepatitis C virus: virology and life cycle. Clin Mol Hepatol. 2013; 19:17–25.

8. Alvisi G, Madan V, Bartenschlager R. Hepatitis C virus and host cell lipids: an intimate connection. RNA Biol. 2011; 8:258–269.

9. Kaplan DE, Sugimoto K, Newton K, Valiga ME, Ikeda F, Aytaman A, et al. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology. 2007; 132:654–666.

10. Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A. 2004; 101:10149–10154.

11. von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology. 2007; 132:667–678.

12. Isken O, Langerwisch U, Jirasko V, Rehders D, Redecke L, Ramanathan H, et al. A conserved NS3 surface patch orchestrates NS2 protease stimulation, NS5A hyperphosphorylation and HCV genome replication. PLoS Pathog. 2015; 11:e1004736.

13. Liang TJ. Current progress in development of hepatitis C virus vaccines. Nat Med. 2013; 19:869–878.

14. Zeisel MB, Barth H, Schuster C, Baumert TF. Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Front Biosci (Landmark Ed). 2009; 14:3274–3285.

15. Bartenschlager R, Penin F, Lohmann V, André P. Assembly of infectious hepatitis C virus particles. Trends Microbiol. 2011; 19:95–103.

16. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol. 2000; 81:1631–1648.

17. Kohaar I, Ploss A, Korol E, Mu K, Schoggins JW, O'Brien TR, et al. Splicing diversity of the human OCLN gene and its biological significance for hepatitis C virus entry. J Virol. 2010; 84:6987–6994.

18. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab. 2010; 21:33–40.

19. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med. 2013; 19:837–849.

20. Horner SM, Gale M Jr. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med. 2013; 19:879–888.

21. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007; 5:453–463.

22. Pawlowska M, Domagalski K, Pniewska A, Smok B, Halota W, Tretyn A. What's new in hepatitis C virus infections in children? World J Gastroenterol. 2015; 21:10783–10789.

23. World Health Organization. WHO Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection. Fact Sheet 2015, No 164. Updated July 2015.

24. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000; 355:887–891.

25. Yeung CY, Lee HC, Chan WT, Jiang CB, Chang SW, Chuang CK. Vertical transmission of hepatitis C virus: Current knowledge and perspectives. World J Hepatol. 2014; 6:643–651.

26. Bortolotti F, Iorio R, Resti M, Cammà C, Marcellini M, Giacchino R, et al. Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period. J Hepatol. 2007; 46:783–790.

27. Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology. 2002; 36:5 Suppl 1. S106–S113.

28. Checa Cabot CA, Stoszek SK, Quarleri J, Losso MH, Ivalo S, Peixoto MF, et al. NICHD International Site Development Initiative Perinatal/Longitudinal Study in Latin American Countries Study Group. Mother-to-child transmission of hepatitis C virus (HCV) among HIV/HCV-coinfected women. J Pediatric Infect Dis Soc. 2013; 2:126–135.

29. Shebl FM, El-Kamary SS, Saleh DA, Abdel-Hamid M, Mikhail N, Allam A, et al. Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages. J Med Virol. 2009; 81:1024–1031.

30. Jara P, Resti M, Hierro L, Giacchino R, Barbera C, Zancan L, et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis. 2003; 36:275–280.

31. Jara P, Hierro L. Treatment of hepatitis C in children. Expert Rev Gastroenterol Hepatol. 2010; 4:51–61.

32. Bortolotti F, Resti M, Marcellini M, Giacchino R, Verucchi G, Nebbia G, et al. Hepatitis C virus (HCV) genotypes in 373 Italian children with HCV infection: changing distribution and correlation with clinical features and outcome. Gut. 2005; 54:852–857.

33. European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis. 2005; 41:45–51.

34. Pembrey L, Newell ML, Tovo PA. EPHN Collaborators. The management of HCV infected pregnant women and their children European paediatric HCV network. J Hepatol. 2005; 43:515–525.

35. Akhter A, Said A. Cutaneous manifestations of viral hepatitis. Curr Infect Dis Rep. 2015; 17:452.

36. Alkhouri N, Zein NN. Hepatitis C in children and adolescents: the good, the bad, and the ugly. Curr Hepat Reports. 2008; 7:145–151.

37. Bortolotti F, Verucchi G, Cammà C, Cabibbo G, Zancan L, Indolfi G, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology. 2008; 134:1900–1907.

38. Bortolotti F, Muratori L, Jara P, Hierro L, Verucchi G, Giacchino R, et al. Hepatitis C virus infection associated with liver-kidney microsomal antibody type 1 (LKM1) autoantibodies in children. J Pediatr. 2003; 142:185–190.

39. Rumbo C, Fawaz RL, Emre SH, Suchy FJ, Kerkar N, Morotti RA, et al. Hepatitis C in children: a quaternary referral center perspective. J Pediatr Gastroenterol Nutr. 2006; 43:209–216.

40. González-Peralta RP, Langham MR Jr, Andres JM, Mohan P, Colombani PM, Alford MK, et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2009; 48:630–635.

41. Barshes NR, Udell IW, Lee TC, O'Mahony CA, Karpen SJ, Carter BA, et al. The natural history of hepatitis C virus in pediatric liver transplant recipients. Liver Transpl. 2006; 12:1119–1123.

42. Chevaliez S, Pawlotsky JM. Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. Best Pract Res Clin Gastroenterol. 2008; 22:1031–1048.

43. Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012; 55:Suppl 1. S43–S48.

44. Park MS, Kim BK, Cheong JY, Kim DJ, Park JY, Kim do Y, et al. Discordance between liver biopsy and FibroTest in assessing liver fibrosis in chronic hepatitis B. PLoS One. 2013; 8:e55759.

45. Russo P, Ruchelli ED, Piccoli DA. Pathology of pediatric gastrointestinal and liver disease. 2nd ed. Berlin: Springer;2014. p. 371–393.

46. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981; 1:431–435.

47. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995; 22:696–699.

48. Theise ND. Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach. Mod Pathol. 2007; 20:Suppl 1. S3–S14.

49. Guido M, Bortolotti F, Leandro G, Jara P, Hierro L, Larrauri J, et al. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? Am J Gastroenterol. 2003; 98:660–663.

50. Goodman ZD, Makhlouf HR, Liu L, Balistreri W, Gonzalez-Peralta RP, Haber B, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology. 2008; 47:836–843.

51. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008; 371:838–851.

52. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015; 63:199–236.

53. El Naghi S, Abdel-Ghaffar TY, El-Karaksy H, Abdel-Aty EF, El-Raziky MS, Allam AA, et al. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children. World J Gastroenterol. 2014; 20:4681–4691.

54. Department of Veterans Affairs Hepatitis C Resource Center. Yee HS, Currie SL, Darling JM, Wright TL. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. Am J Gastroenterol. 2006; 101:2360–2378.

55. Kamal SM. Hepatitis C genotype 4 therapy: increasing options and improving outcomes. Liver Int. 2009; 29:Suppl 1. 39–48.

56. Varghese R, Al-Khaldi J, Asker H, Fadili AA, Al Ali J, Hassan FA. Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin. Hepatogastroenterology. 2009; 56:218–222.

57. Lee CK, Jonas MM. Treating HCV infection in children. Clin Liver Dis. 2015; 5:14–16.

58. Hofmann WP, Sarrazin C, Zeuzem S. Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int. 2012; 109:352–358.

59. Navaneethan U, Kemmer N, Neff GW. Predicting the probable outcome of treatment in HCV patients. Therap Adv Gastroenterol. 2009; 2:287–302.

60. Noureddin M, Ghany MG. Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C. Gastroenterol Clin North Am. 2010; 39:649–658.

61. FDA News Release. FDA approves rapid test for antibodies to hepatitis C virus. Silver Spring: U.S. Food and Drug Administration;2010.

62. Yeung LT, Roberts EA. Current issues in the management of paediatric viral hepatitis. Liver Int. 2010; 30:5–18.

63. Scherzer TM, Reddy KR, Wrba F, Hofer H, Staufer K, Steindl-Munda P, et al. Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C. J Viral Hepat. 2008; 15:659–665.

64. Iorio R, Giannattasio A, Sepe A, Terracciano LM, Vecchione R, Vegnente A. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis. 2005; 41:1431–1437.

65. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461:399–401.

66. Villar LM, Cruz HM, Barbosa JR, Bezerra CS, Portilho MM, Scalioni Lde P. Update on hepatitis B and C virus diagnosis. World J Virol. 2015; 4:323–342.

67. Jara P, Hierro L, de la Vega A, Díaz C, Camarena C, Frauca E, et al. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J. 2008; 27:142–148.

68. Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology. 2005; 41:1013–1018.

69. Bortolotti F, Iorio R, Nebbia G, Marcellini M, Giacchino R, Zancan L, et al. Interferon treatment in children with chronic hepatitis C: long-lasting remission in responders, and risk for disease progression in non-responders. Dig Liver Dis. 2005; 37:336–341.

70. Jonas MM, Balistreri W, Gonzalez-Peralta RP, Haber B, Lobritto S, Mohan P, et al. Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial. Hepatology. 2012; 56:523–531.

71. Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr. 2012; 54:838–855.

72. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364:2417–2428.

73. Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015; 148:108–117.

74. Forns X, Prieto M, Charlton M, McHutchison JG, Symonds WT, Denning J, et al. O62 sofosbuvir compassionate use program for patients with severe recurrent hepatitis c including fibrosing cholestatic hepatitis following liver transplantation. J Hepatol. 2014; 60:Suppl. S26.

75. Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkorn K, Rojter S, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016; DOI: 10.1002/hep.28467. [Epub ahead of print].

76. Reddy KR, Everson GT, Flamm SL, Denning JM, Arterburn S, Brandt-Sarif T, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post-transplant recurrence: preliminary results of a prospective, multicenter study. Hepatology. 2014; 60:200A–201A.

77. Mantry P, Kwo P, Coakley E, Te H, Vargas H, Brown RS, et al. High sustained virologic response rates in liver transplant recipients with recurrent HCV genotype 1 infection receiving ABT-450/R/ombitasvir+dasabuvir plus ribavirin. Paper presented at: 65th Annual Meeting of the American Association for the Study of Liver Diseases. 2014 Nov 7-11; Boston, USA. p. 298A.

78. Brown RS, Reddy KR, O'Leary JG, Kuo A, Morelli G, Stravitz RT, et al. Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study. Paper presented at: 65th Annual Meeting of the American Association for the Study of Liver Diseases. 2014 Nov 7-11; Boston, USA. p. 1269A.

79. Leroy V, Dumortier J, Coilly A, Sebagh M, Fougerou-Leurent C, Radenne S, et al. High rates of virological response and major clinical improvement during sofosbuvir and daclatasvir-based regimens for the treatment of fibrosing cholestatic HCV-recurrence after liver transplantation: the ANRS CO23 CUPILT study. Transpl Int. 2015; 28:14.

80. Lawitz E, Poordad F, Hyland RH, Liu L, Dvory HS, Pang PS, et al. High rates of SVR in treatment-experienced patients with genotype 1 HCV infection and cirrhosis after treatment with ledipasvir/sofosbuvir and vedroprevir with or without ribavirin for 8 weeks. Paper presented at: 66th Annual Meeting of the American Association for the Study of Liver Diseases. 2015 Nov 13-17; Boston, USA. p. 337A.

81. Kwo P, Bennett M, Wang S, Vargas HE, Wyles D, Overcash JS, et al. SURVEYOR-II: high SVR4 rates achieved with the next generation NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 in non-cirrhotic treatment-naïve and treatment-experienced patients with HCV genotype 3 infection. Paper presented at: Frontiers in Drug Development for Viral Hepatitis. 2015 Dec 6-10; Wailea, USA. p. 337A–338A.

82. Alessandra MA, Stuart K. Roberts SK, Pianko S, Thompson AJ, Cooper C, et al. Sofosbuvir/GS-5816 fixed dose combination for 12 weeks compared to sofosbuvir with ribavirin for 24 weeks in genotype 3 hcv infected patients: the randomized controlled phase 3 ASTRAL-3 study. Hetatology. 2015; 62:Suppl 1. 338A.

83. Wyles D, Sulkowski M, Wang S, Bennett M, Vargas HE, Overcash JS, et al. SURVEYOR-II: high SVR4 rates achieved with the next generation NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 in non-cirrhotic treatment-naïve and treatment-experienced patients with HCV genotype 2 infection. Paper presented at: 66th Annual Meeting of the American Association for the Study of Liver Diseases. 2015 Nov 13-17; Boston, USA. p. 339A.

84. Asselah T, Reesink H, Gerstoft J, de Ledinghen V, Pockros P, Robertson M, et al. High efficacy of elbasvir and grazoprevir with or without ribavirin in 103 treatment-naive and experienced patients with HCV genotype 4 infection: a pooled analysis. Paper presented at: 66th Annual Meeting of the American Association for the Study of Liver Diseases. 2015 Nov 13-17; Boston, USA. p. 339A.

85. Herzer K, Welzel TM, Ferenci P, Petersen J, Gschwantler M, Cornberg M, et al. Daclatasvir in combination with sofosbuvir with or without ribavirin is safe and efficacious in liver transplant recipients with HCV recurrence: interim results of a European multicenter compassionate use program. Paper presented at: 66th Annual Meeting of the American Association for the Study of Liver Diseases. 2015 Nov 13-17; Boston, USA. p. 339A.

86. Welzel TM, Petersen J, Ferenci P, Gschwantler M, Herzer K, Cornberg M, et al. Safety and efficacy of daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV genotype 3 infection: interim results of a multicenter European compassionate use program. Paper presented at: 66th Annual Meeting of the American Association for the Study of Liver Diseases. 2015 Nov 13-17; Boston, USA. p. 225A.

87. Lawitz E, Poordad F, Gutierrez JA, Kakuda T, Picchio G, Beets G, et al. SVR12 results from the Phase II, open-label IMPACT. Study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease. Hepatology. 2015; 62:Suppl 1. 227A.

88. Poordad F, Felizarta F, Asatryan A, Hassanein TI, Aguilar HI, Lalezari JP, et al. 98%-100% SVR4 in HCV genotype 1 non-cirrhotic treatment-naïve or pegylated interferon/ribavirin null responders with the combination of the next generation NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 (SURVEYOR-1). Hepatology. 2015; 62:Suppl 1. 228A.

89. Gane EJ, Hyland RH, Yang Y, Stamm LM, Brainard DM, McHutchison JG, et al. Sofosbuvir/GS-5816+GS-9857 for 6 or 8 weeks in genotype 1 or 3 HCV-infected patients. Hepatology. 2015; 62:Suppl 1. 227A.

90. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015; 62:932–954.